NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that it will be presenting at the LD 500 Virtual Investor Conference scheduled to take place from September 1-4, 2020.
Michael Feldschuh, CEO and President of Daxor, is scheduled to present virtually on Wednesday, September 2, 2020, at 9:20 am ET followed by a live Q&A session with registered investors and other conference attendees. Mr. Feldschuh will also participate in virtual one-on-one meetings with investors and analysts throughout the event.
The Company will provide updates on recent developments within its diagnostic division, ongoing clinical trials, and other timely topics.
The presentation will be webcast live and available for replay here: https://www.webcaster4.com/Webcast/Page/2019/36866
Interested investors may request a meeting time by directly contacting Eric Lahiji at email@example.com
For those interested in attending the event, please register here: https://ld-micro-conference.events.issuerdirect.com/
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.